Regeneron eyes long-lasting Eylea in deal with Ocular

The companies said the new drug would benefit consumers by enabling lower dosing and fewer trips to the doctor.

By Jacob Bell • Oct. 13, 2016

AstraZeneca snaps up Amgen site in Colorado

The newly acquired facility will support another Colorado plant AstraZeneca bought from Amgen last year, both of which are focused on biologics. 

By Suzanne Elvidge • Oct. 13, 2016

Verily, 3M team up to measure healthcare costs

Formerly Google Life Sciences, Verily has also recently launched partnerships with a range of big pharmas, including Sanofi and GSK. 

By Joe Cantlupe • Oct. 12, 2016

Merck KGaA, Pfizer and Transgene team up on cancer vaccine

The French biotech announced collaborations with Merck KGaA and Pfizer to evaluate its HPV-positive head and neck cancer vaccine in combo with avelumab.

By Joe Cantlupe • Oct. 12, 2016

Piramal picks up J&J drugs in strategic move

The Indian company is bulking up on generic injectables to complement its inhalable offerings. 

By Lisa LaMotta • Oct. 12, 2016

Merck inks pay-for-performance deal to boost diabetes drugs

Under an agreement with Aetna, rebates for Januvia and Janumet will be tied to treatment outcomes among type 2 diabetes patients. 

By Ned Pagliarulo • Oct. 11, 2016

Medivir slashes jobs, projects in new cancer focus

The Swedish biotech is in the midst of a major reorganization, with plans to split in two by the end of the year. 

By Suzanne Elvidge • Oct. 11, 2016

Takeda broadens oncology pipeline with Crescendo deal

Under CEO Christophe Weber, Takeda has moved to focus its efforts on development of oncology, gastrointestinal and CNS therapeutics. 

By Ned Pagliarulo • Oct. 10, 2016

Teva sells Actavis generics in UK

The sale is part of a divestiture required as under Teva's acquisition of Allergan’s generic business.

By Joe Cantlupe • Oct. 7, 2016

AstraZeneca conducts fourth sale this week

The big pharma continues to shed non-core assets as it realigns its portfolio to focus on key areas. 

By Lisa LaMotta • Oct. 7, 2016

Pfizer continues trend of shedding non-core assets

The big pharma gets rid of more Hospira assets and gains a stake in pure-play infusion therapy company.

By Suzanne Elvidge • Oct. 7, 2016

Prescribed Reading: Pharma re-focuses, face-off at ESMO, Hep C boxed

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 6, 2016

Catalent out-licenses ADC to Triphase

Triphase Accelerator of San Diego purchased rights to Catalent’s anti-body drug conjugate platform to make clinical headway against lymphoma.

By Joe Cantlupe • Oct. 6, 2016

Celltrion finds new partner after Pfizer exit

The partnership is the latest in a string of biosimilar marketing and production pacts that have popped up in the last few years.

By Jacob Bell • Oct. 6, 2016

BI sells to Elanco to complete Sanofi swap

Eli Lilly, which owns Elanco, will pay $885 million for the portfolio of cat and dog vaccines, adding to its growing animal health business. 

By Suzanne Elvidge • Oct. 6, 2016

OWC Pharma secures funding for cannabinoid drug

Interest in cannabidiol-based drugs has grown, particularly as GW Pharma continues to have success in late-stage clinical trials for Epidiolex. 

By Suzanne Elvidge • Oct. 5, 2016

AstraZeneca: Everything must go!

The British pharma announced its third out-licensing deal in as many days as it continues to shed non-core assets. 

By Lisa LaMotta • Oct. 5, 2016

Daiichi Sankyo links up with AgonOx in latest I/O deal

The Japanese drugmaker has built out its oncology pipeline, but suffered a setback when a Phase 3 lung cancer trial fell short of goal earlier this year. 

By Suzanne Elvidge • Oct. 5, 2016

Celgene CEO: myeloma and glioblastoma both priorities

Following a $600 million buy for Engmab, CEO Mark Alles said the company is expanding beyond multiple myeloma research toward brain cancer. 

By Joe Cantlupe • Oct. 4, 2016

AstraZeneca continues fire sale

The British pharma has been busy selling off non-core assets as part of an overall divestment and refocusing strategy. 

By Lisa LaMotta • Oct. 4, 2016

Amgen inks latest high price-tag research collaboration

With global oncology and neuroscience markets poised for growth, both Amgen and Nuevolution have been active on the deal-making front.

By Jacob Bell • Oct. 4, 2016

Sarepta steps up DMD dealmaking

Less than a week after signing a research deal with Catabasis Pharma, Sarepta paid $40 million upfront for rights to a DMD drug from Summit Therapeutics.

By Ned Pagliarulo • Oct. 4, 2016

AstraZeneca furthers sell-off strategy with new deal

The British pharma out-licensed rights to an inflammatory disease drug to Allergan, receiving $250 million upfront as it narrows its focus on key therapeutic areas. 

By Ned Pagliarulo • Oct. 3, 2016

UPDATED: BI plays hot potato with Hanmi, returns cancer drug

The German drugmaker abruptly abandoned a mid-stage lung cancer drug after reports surfaced about patient deaths. 

By Lisa LaMotta • Sept. 30, 2016

Bluebird flies into TCR deal with Medigene

Medigene will get $15 million upfront to develop TCR candidates, but a long chain of milestones could push total deal value much higher. 

By Suzanne Elvidge • Sept. 30, 2016